According to the latest National Comprehensive Cancer Network (NCCN) guidelines for BC, premenopausal and postmenopausal patients are treated with tamoxifen (selective estrogen modulator, SERM) and tamoxifen or aromatase inhibitors (AIs), respectively. The gene discussed is CYP19A1; the disease is breast cancer.